logo/base Created with Sketch.

Software SmartExam

Enhance FibroScan® capabilities for improved management of fatty liver patients

chevron chevron

Continuous CAP

Improve reliability in the diagnosis and monitoring of steatosis

With SmartExam, a new computation method allows continuous measurement of CAP during the entire examination. In addition, when CAP measurement doesn’t meet the quality criteria they are automatically rejected.

SmartExam with Continuous CAP decreases variability by 50%.1

Continuous CAP can be measured on children with the S+ probe* to prevent them from undergoing biopsy.

Update your FibroScan with SmartExam

Deeper assessment of liver fibrosis and steatosis

Extend usage among severely obese patients:

With SmartExam, the maximum recommended PCD (Probe to Capsula Distance) is 45 mm (vs 35 mm without SmartExam) representing an increase of 28%.

Update your FibroScan with SmartExam

Dedicate more time to the patient care

E (liver stiffness) and CAP gauges automatically increase when measurements are validated. These measurement depths are automatically adapted to patient’s morphology.

 

Operator gets notified when liver is too deep.

 

These task automation features were designed to further enhance the standardisation of the FibroScan® examination.

 

SmartExam is available as an option.

Learn more

Our liver health solutions

  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron
  • Scores FibroScan® based

    FibroScan®-based Scores

    Enhance FibroScan® liver disease assessment with biological markers

    chevron
  • FibroScan® Guided VCTE

    Guided VCTE®

    Seamless liver health assessment for all

    chevron
  • FibroScan® Mini+ 430

    FibroScan® by echosens

    The non-invasive solution for comprehensive management of liver health

    chevron

What our users say

SmartExam is a key technology for improving standardization of FibroScan® and eliminate liver stiffness and CAP measurements bias caused by the long probe-to-capsule distance in patients with obesity; thus, it increases the diagnostic accuracy and reliability to identify fatty liver and assess fibrosis in this clinical population.

Yusuf Yilmaz

Professor and MD. Gastroenterology and Hepatology - Marmara University Hospital, Istanbul, Turkey

The obese population that we receive for FibroScan examinations has increased substantially in recent years. CAP has become essential to our prescribers to precisely monitor patient's steatosis. SmartExam allows us to address difficult patients and to provide reliable results to our prescribers.

FibroScan® nurse referent

at Cochin University Hospital, Paris, France

Request a demo!

Interested in FibroScan®?

Contact us

Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.

*CAP is not available on S+ probe in all countries.

1.SmartExam: E. Bardou-Jacquet et al, Validation of the Continuous Controlled Attenuation Parameter (CAPc) using the MRI-PDFF as reference. EASL 2022 poster #FRI-228​.